Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wasserman

Showing results (31-40 of 259) with videos related to

Pageof 26
Sort By:
Immunology and Allergy Clinics of North America|November 24, 2018
Personalized Therapy: Immunoglobulin Replacement for Antibody DeficiencyRichard L Wasserman
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 5, 2025
Remote oral immunotherapy updosing: Access, safety, and economicsRichard L Wasserman
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 11, 2022
Reply to high cost of immunoglobulin replacement therapy: Causes and implicationsRichard L Wasserman
Immunotherapy|September 6, 2017
Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseasesRichard L Wasserman
Pediatrics|September 1, 1984
A prospective study of the impact of home monitoring on the familyA L Wasserman
Patient Preference and Adherence|November 19, 2009
Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectationsRichard L Wasserman
Immunotherapy|October 17, 2017
Gammaplex<sup>®</sup> 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpuraRichard L Wasserman
Archives of General Psychiatry|December 1, 1994
All prepaid health care systems are not equalA L Wasserman
Immunotherapy|June 5, 2014
Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficienciesRichard L Wasserman
The Western Journal of Medicine|August 3, 2001
Seizure disorders: Part 1. Classification and diagnosisS Kammerman, L Wasserman
Pageof 26

Showing results (31-40 of 259) with videos related to

Sort By:
Pageof 26
Immunology and Allergy Clinics of North America|November 24, 2018
Personalized Therapy: Immunoglobulin Replacement for Antibody DeficiencyRichard L Wasserman
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 5, 2025
Remote oral immunotherapy updosing: Access, safety, and economicsRichard L Wasserman
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 11, 2022
Reply to high cost of immunoglobulin replacement therapy: Causes and implicationsRichard L Wasserman
Immunotherapy|September 6, 2017
Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseasesRichard L Wasserman
Pediatrics|September 1, 1984
A prospective study of the impact of home monitoring on the familyA L Wasserman
Patient Preference and Adherence|November 19, 2009
Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectationsRichard L Wasserman
Immunotherapy|October 17, 2017
Gammaplex<sup>®</sup> 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpuraRichard L Wasserman
Archives of General Psychiatry|December 1, 1994
All prepaid health care systems are not equalA L Wasserman
Immunotherapy|June 5, 2014
Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficienciesRichard L Wasserman
The Western Journal of Medicine|August 3, 2001
Seizure disorders: Part 1. Classification and diagnosisS Kammerman, L Wasserman
Pageof 26